380 related articles for article (PubMed ID: 22511580)
1. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.
Trejo CL; Juan J; Vicent S; Sweet-Cordero A; McMahon M
Cancer Res; 2012 Jun; 72(12):3048-59. PubMed ID: 22511580
[TBL] [Abstract][Full Text] [Related]
2. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Jänne PA; Johnson BE; Chin L; Wong KK
Cancer Res; 2007 May; 67(10):4933-9. PubMed ID: 17510423
[TBL] [Abstract][Full Text] [Related]
3. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
[TBL] [Abstract][Full Text] [Related]
4. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
5. TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis.
Shai A; Dankort D; Juan J; Green S; McMahon M
Cancer Res; 2015 Aug; 75(15):3167-80. PubMed ID: 26001956
[TBL] [Abstract][Full Text] [Related]
6. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.
Lito P; Saborowski A; Yue J; Solomon M; Joseph E; Gadal S; Saborowski M; Kastenhuber E; Fellmann C; Ohara K; Morikami K; Miura T; Lukacs C; Ishii N; Lowe S; Rosen N
Cancer Cell; 2014 May; 25(5):697-710. PubMed ID: 24746704
[TBL] [Abstract][Full Text] [Related]
7. Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression.
Trejo CL; Green S; Marsh V; Collisson EA; Iezza G; Phillips WA; McMahon M
Cancer Res; 2013 Nov; 73(21):6448-61. PubMed ID: 24019382
[TBL] [Abstract][Full Text] [Related]
8. Genetic predictors of MEK dependence in non-small cell lung cancer.
Pratilas CA; Hanrahan AJ; Halilovic E; Persaud Y; Soh J; Chitale D; Shigematsu H; Yamamoto H; Sawai A; Janakiraman M; Taylor BS; Pao W; Toyooka S; Ladanyi M; Gazdar A; Rosen N; Solit DB
Cancer Res; 2008 Nov; 68(22):9375-83. PubMed ID: 19010912
[TBL] [Abstract][Full Text] [Related]
9. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract][Full Text] [Related]
10. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ
Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556
[TBL] [Abstract][Full Text] [Related]
11. A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.
Lyubynska N; Gorman MF; Lauchle JO; Hong WX; Akutagawa JK; Shannon K; Braun BS
Sci Transl Med; 2011 Mar; 3(76):76ra27. PubMed ID: 21451123
[TBL] [Abstract][Full Text] [Related]
12. Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF.
Cisowski J; Sayin VI; Liu M; Karlsson C; Bergo MO
Oncogene; 2016 Mar; 35(10):1328-33. PubMed ID: 26028035
[TBL] [Abstract][Full Text] [Related]
13. An NKX2-1/ERK/WNT feedback loop modulates gastric identity and response to targeted therapy in lung adenocarcinoma.
Zewdu R; Mehrabad EM; Ingram K; Fang P; Gillis KL; Camolotto SA; Orstad G; Jones A; Mendoza MC; Spike BT; Snyder EL
Elife; 2021 Apr; 10():. PubMed ID: 33821796
[TBL] [Abstract][Full Text] [Related]
14. MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF
Sale MJ; Balmanno K; Saxena J; Ozono E; Wojdyla K; McIntyre RE; Gilley R; Woroniuk A; Howarth KD; Hughes G; Dry JR; Arends MJ; Caro P; Oxley D; Ashton S; Adams DJ; Saez-Rodriguez J; Smith PD; Cook SJ
Nat Commun; 2019 May; 10(1):2030. PubMed ID: 31048689
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
Green S; Trejo CL; McMahon M
Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
[TBL] [Abstract][Full Text] [Related]
16. The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.
Andreadi C; Cheung LK; Giblett S; Patel B; Jin H; Mercer K; Kamata T; Lee P; Williams A; McMahon M; Marais R; Pritchard C
Genes Dev; 2012 Sep; 26(17):1945-58. PubMed ID: 22892241
[TBL] [Abstract][Full Text] [Related]
17. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors.
Dankort D; Filenova E; Collado M; Serrano M; Jones K; McMahon M
Genes Dev; 2007 Feb; 21(4):379-84. PubMed ID: 17299132
[TBL] [Abstract][Full Text] [Related]
18. PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma.
Deuker MM; Marsh Durban V; Phillips WA; McMahon M
Cancer Discov; 2015 Feb; 5(2):143-53. PubMed ID: 25472943
[TBL] [Abstract][Full Text] [Related]
19. MEK1/2 inhibition decreases lactate in BRAF-driven human cancer cells.
Falck Miniotis M; Arunan V; Eykyn TR; Marais R; Workman P; Leach MO; Beloueche-Babari M
Cancer Res; 2013 Jul; 73(13):4039-49. PubMed ID: 23639941
[TBL] [Abstract][Full Text] [Related]
20. Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.
Simmons BH; Lee JH; Lalwani K; Giddabasappa A; Snider BA; Wong A; Lappin PB; Eswaraka J; Kan JL; Christensen JG; Shojaei F
Cancer Chemother Pharmacol; 2012 Aug; 70(2):213-20. PubMed ID: 22684718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]